Summary of Research on Long COVID Treatment Using Stellate Ganglion Block
Introduction
Long COVID, also known as post-acute COVID-19 syndrome (PASC), is characterized by a range of persistent symptoms that can last for several weeks or months after the initial acute infection with SARS-CoV-2. These symptoms can be debilitating and significantly impact the quality of life of those affected.
Stellate ganglion block (SGB) is a minimally invasive procedure that involves injecting a local anesthetic into the stellate ganglion, a cluster of nerves located in the neck. SGB has been used to treat a variety of conditions, including pain, anxiety, and post-traumatic stress disorder (PTSD).
Emerging Evidence for SGB in Long COVID
Preliminary research suggests that SGB may be a promising treatment for long COVID. A small retrospective cohort study published in Cureus in September 2023 found that 86% of patients with long COVID experienced a reduction in their symptoms following SGB treatment. The most common symptoms that improved included fatigue, brain fog, dysautonomia, and pain.
Another study, published in medRxiv in August 2023, reported similar findings. In this study, 41 patients with long COVID received SGB and 83% of them experienced a significant improvement in their symptoms. The most common symptoms that improved were fatigue, dyspnea, and cognitive dysfunction.
Mechanism of Action
The exact mechanism by which SGB may improve symptoms of long COVID is still being investigated. However, it is thought that SGB may help to reset the autonomic nervous system, which is believed to play a role in the development of long COVID symptoms.